West Pharmaceutical Stock Surges 7%, Adding $1.9 Billion, As Company Lifts 2026 Outlook

The injectable-drug packaging supplier raised its 2026 sales and earnings targets, but guided fourth-quarter growth well below the third quarter.

Share
West Pharmaceutical Stock Surges 7%, Adding $1.9 Billion, As Company Lifts 2026 Outlook

West Pharmaceutical, which makes containment and delivery systems for injectable drugs, saw its shares climb 6.66% to $430.54 in Thursday trading, as of 11:47 a.m. ET, a new 52-week high that added about $1.9 billion in market value. The move followed a third-quarter report that raised the company's 2026 forecast for sales and adjusted earnings.

A raised outlook on wider margins

Third-quarter revenue was $874.5 million, up 8.7% from a year earlier, with adjusted earnings of $2.66 a share, the company reported. Investors responded to stronger margins on premium vial stoppers.

West now expects 2026 revenue of $3.41 billion to $3.42 billion and adjusted earnings of $9.38 to $9.48 per share. It also said it bought back $231 million of its stock in the quarter.

The shares were on pace for a fourth straight daily gain and their biggest one-day rise since April 23. West's market value stood at $30.3 billion Thursday.

A beat with a cooling fourth quarter

Management said on the earnings call that the margin gains are not "the New Floor," and guided fourth-quarter growth well below the third quarter's pace.

High-value components, led by GLP-1-related products, made up 53% of revenue, the company said.

Up 47% this year

West sells stoppers, seals, syringe and cartridge components, vials and self-injection devices to biologic, generic, pharmaceutical, diagnostic and medical device companies. Its revenue comes from two segments: Proprietary Products, sold mainly to drug companies, and Contract-Manufactured Products, which designs and assembles complex devices.

The stock was up about 47% year to date as of Wednesday's close, well ahead of the S&P 500's roughly 13% gain.

Thursday's rally leaves the stock at a 52-week high, set against management's own warning that fourth-quarter growth will be well below the third quarter's.

Sources

More on West Pharmaceutical

All West Pharmaceutical (WST) coverage →